Trending Topic

3d illustration of human body liver
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver […]

Omid Hamid, ASCO 2021: Nemvaleukin Alfa and the ARTISTRY-2 Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 13th 2021

touchONCOLOGY joins Dr Omid Hamid (Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, Los Angeles, CA, USA) at ASCO 2021 to discuss nemvaleukin alfa and the ARTISTRY-2 trial.

The abstract ‘Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2’ (NCT03861793) (abstract number 2552) was presented at the 2021 ASCO Annual Meeting.

Abstract

Poster

Questions
1. Could you tell us a little about nemvaleukin alfa and its mechanism of action? (0:15-01:32)

2. What are the aims of the ARTISTRY clinical trial program, and what have we learned to date? (01:32-02:49)

3. Which tumour types were included in ARTISTRY-2? (02:49-04:09)

4. What were the efficacy and safety findings of ARTISTRY-2? (04:09-05:15)

5. What will be the next steps in the ARTISTRY clinical trial program? (05:15-07:26)

Disclosures: Consulting/Advisory Boards: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, Seattle, Genetics, Tempus, Zelluna. Speaker Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron. Contracted Research (For Institution): Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.

Filmed in coverage of the 2021 ASCO Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup